Bayesian Capital Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Bayesian Capital Management’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-17,400	Closed	-$132K	–	157
2025 Q3	$132K	Buy	+17,400	New	+$145K	0.03%	480
2025 Q1	–	Sell	-25,700	Closed	-$193K	–	621
2024 Q4	$193K	Buy	+25,700	New	+$195K	0.02%	572
2024 Q3	–	Sell	-43,200	Closed	-$267K	–	693
2024 Q2	$267K	Buy	+43,200	New	+$238K	0.03%	535
2024 Q1	–	Sell	-60,600	Closed	-$363K	–	782
2023 Q4	$363K	Sell	60,600 -18,100	-23%	-$105K	0.04%	454
2023 Q3	$557K	Buy	78,700 +63,700	+425%	+$458K	0.06%	350
2023 Q2	$106K	Buy	+15,000	New	+$120K	0.01%	689
2022 Q4	–	Sell	-40,454	Closed	-$510K	–	787
2022 Q3	$510K	Buy	+40,454	New	+$521K	0.1%	277
2020 Q2	–	Sell	-27,100	Closed	-$54K	–	533
2020 Q1	$54K	Buy	+27,100	New	+$74.6K	0.01%	721

Other funds holding BCRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Bayesian Capital Management's BCRX Position: Q4 2025 in Review

Bayesian Capital Management sold out of BioCryst Pharmaceuticals (BCRX) in Q4 2025, closing a stake of 17,400 shares — an estimated $132K sold.

Bayesian Capital Management first reported a position in BCRX in Q1 2020 and held it in 8 quarters. The position peaked at $557K in Q3 2023. 272 funds tracked by Wall St. Rank hold BCRX as of Q4 2025.

Bayesian Capital Management reported no remaining BioCryst Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Bayesian Capital Management sold 17,400 BioCryst Pharmaceuticals shares in Q4 2025, an estimated $132K.
Bayesian Capital Management first reported a position in BioCryst Pharmaceuticals in Q1 2020 and held it in 8 quarters.
Bayesian Capital Management's BioCryst Pharmaceuticals position peaked at $557K in Q3 2023.
272 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2025.

Based on Bayesian Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.